Alzheimer’s disease (AD) is characterized by the accumulation and aggregation of tau and amyloid-β (Aβ). The pathophysiology and progression of AD are facilitated by the neurotoxic effects of these aggregated proteins, resulting in neurodegeneration and memory loss. In this context, the interaction between tau and Aβ42 is considered, but the mechanism underlying their pathogenic interplay remains unclear. Here, we addressed this question by studying the aggregation of full-length, unmodified tau and Aβ42 at physiologically low concentrations using atomic force microscopy (AFM). AFM imaging and data analyses demonstrate an increase in tau aggregation in the presence of Aβ42, characterized by increased sizes and number of aggregates. Importantly, tau aggregation occurs without the need for phosphorylation or any other post-translational changes. The analysis of the data demonstrates that tau and Aβ42 form co-aggregates, with no visible accumulation of Aβ42 aggregates alone. Given that the catalysis of tau aggregation by Aβ42 is observed at physiological low nanomolar concentrations of Aβ42, the finding suggests that such aggregation catalysis of tau by Aβ42 can be a molecular mechanism underlying the pathological tau aggregation process associated with the onset and development of Alzheimer’s disease.
Borrowing external data can improve estimation efficiency but may introduce bias when populations differ in covariate distributions or outcome variability. A proper balance needs to be maintained between the two datasets to justify the borrowing. We propose a propensity score weighting borrowing-by-parts power prior (PSW-BPP) that integrates causal covariate adjustment through propensity score weighting with a flexible Bayesian borrowing approach to address these challenges in a unified framework. The proposed approach first applies propensity score weighting to align the covariate distribution of the external data with that of the current study, thereby targeting a common estimand and reducing confounding due to population heterogeneity. The weighted external likelihood is then incorporated into a Bayesian model through a borrowing-by-parts power prior, which allows distinct power parameters for the mean and variance components of the likelihood, enabling differential and calibrated information borrowing. Additionally, we adopt the idea of the minimal plausibility index (mPI) to calculate the power parameters. This separate borrowing provides greater robustness to prior-data conflict compared with traditional power prior methods that impose a single borrowing parameter. We study the operating characteristics of PSW-BPP through extensive simulation and a real data example. Simulation studies demonstrate that PSW-BPP yields more efficient and stable estimation than no borrowing and fixed borrowing, particularly under moderate covariate imbalance and outcome heterogeneity. The proposed framework offers a principled and extensible methodological contribution for Bayesian inference with external data in observational and hybrid study designs.
Alzheimer's disease (AD) is characterized by the accumulation and aggregation of tau and amyloid-β (Aβ). The pathophysiology and progression of AD are facilitated by the neurotoxic effects of these aggregated proteins resulting in neurodegeneration and memory loss. In this context, the interaction between tau and Aβ42 is considered but the mechanism behind their pathology associated interplay is not clear. Here, we addressed this question by studies of aggregation of full-length, unmodified tau and Aβ42 at physiologically low concentrations using atomic force microscopy (AFM). AFM imaging and data analyses demonstrate an increase in tau aggregation in the presence of Aβ42, characterized by increased sizes and number of aggregates. Importantly, tau aggregation occurs without the need for phosphorylation or any other post-translational changes. The analysis of the data demonstrates that tau and Aβ42 form co-aggregates, with no visible accumulation of Aβ42 aggregates alone. Given that the catalysis of tau aggregation by Aβ42 is observed at physiological low nanomolar concentrations of Aβ42, the finding suggests that such aggregation catalysis of tau by Aβ42 can be a molecular mechanism underlying pathological tau aggregation process associated with onset and development of Alzheimer’s disease.